VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ARDT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ARDTArdent Health Inc.
$14.40$2.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksARDTFinancials

Ardent Health Inc. (ARDT) Income Statement

7Y historyFree accessUpdated daily

Quarterly revenue has held near $1.6B with reported gross margin fluctuating between 6.0% and 15.9% in recent quarters, appearing to reflect cost reclassification rather than underlying pricing power, while net margin remained thin at 2.7% in 2026Q3.

Income StatementBalance SheetCash FlowRatios

ARDT Income Statement

Annual statement

ARDT Income Statement

Ardent Health Inc. (ARDT) annual income statement — 7-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'18Dec'17Dec'16
Sales/Revenue6.45B6.32B5.97B5.41B5.13B4.16B3B2.11B
Revenue Growth %2.03%6.01%10.29%5.45%23.25%38.63%42.6%-
Cost of Goods Sold5.18B155.7M1.03B140.84M955.17M000
COGS % of Revenue-2.46%17.32%2.6%18.62%---
Gross Profit1.28B6.17B4.93B5.27B4.17B4.16B3B2.11B
Gross Margin %19.79%97.54%82.68%97.4%81.38%100%100%100%
Gross Profit Growth %-25.05%-6.37%26.21%0.3%38.63%42.6%-
Operating Expenses953.28M5.84B4.53B5.04B3.96B4.08B2.77B2.11B
OpEx % of Revenue-92.39%75.88%93.15%77.15%97.93%92.35%100%
Selling, General & Admin376.24M1.19B3.88B3.62B3.37B2.68B1.17B1.95B
SG&A % of Revenue-18.86%65.11%66.97%65.73%64.34%38.86%92.58%
Research & Development0000015.7M19.9M0
R&D % of Revenue-----0.38%0.66%-
Other Operating Expenses4M4.65B642.51M1.42B585.81M000
Operating Income324.21M325.58M405.76M229.5M217.03M149.76M121.77M84.75M
Operating Margin %5.02%5.15%6.8%4.24%4.23%3.6%4.06%4.03%
Operating Income Growth %--19.76%76.8%5.75%44.92%22.98%43.68%-
EBITDA490.63M481.29M552.05M370.35M355.2M292.95M231.3M156.27M
EBITDA Margin %7.6%7.61%9.25%6.85%6.92%7.04%7.7%7.42%
EBITDA Growth %-48.25%-12.82%49.06%4.26%21.25%26.65%48.02%-
D&A (Non-Cash Add-back)166.42M155.7M146.29M140.84M138.17M143.19M109.53M71.51M
EBIT317.06M341.56M428.64M209.15M393.53M101.68M121.38M71.32M
Net Interest Income-51.01M-55.2M-65.58M-65.42M-82.05M-108.59M-70.74M-26.95M
Interest Income00000000
Interest Expense51.01M55.2M65.58M65.42M82.05M108.59M70.74M26.95M
Other Income/Expense-33.02M-39.23M-42.7M-77.89M94.45M-264.37M-71.13M-40.38M
Pretax Income291.19M286.36M363.06M151.61M311.48M-114.62M50.64M44.37M
Pretax Margin %4.51%4.53%6.09%2.8%6.07%-2.75%1.69%2.11%
Income Tax60.36M56.22M63.35M22.64M46.11M-11.29M49.87M8.02M
Effective Tax Rate %20.73%19.63%17.45%14.93%14.8%9.85%98.47%18.08%
Net Income146.22M135.81M210.34M50.29M188.91M-143.02M-35.65M14.6M
Net Margin %2.27%2.15%3.53%0.93%3.68%-3.44%-1.19%0.69%
Net Income Growth %-28.69%-35.43%318.24%-73.38%232.08%-301.21%-344.15%-
Net Income (Continuing)230.83M230.13M299.71M128.98M265.37M-103.33M774K36.35M
Discontinued Operations00000000
Minority Interest385.5M-1.25M390.98M411.42M411.26M380.19M382.55M129.47M
EPS (Diluted)1.030.961.580.351.32-1.01-0.250.10
EPS Growth %-31.33%-39.24%351.43%-73.48%230.69%-304%-350%-
EPS (Basic)-0.961.590.351.32-1.01-0.250.10
Diluted Shares Outstanding141.7M141.45M132.75M143.26M143.26M140.96M140.96M140.96M
Basic Shares Outstanding140.59M140.76M132.44M143.26M143.26M140.96M140.96M140.96M
Dividend Payout Ratio----92.54%---

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Margin compression and labor inflation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Plateau Masks Volume Stabilization

Based on reported figures, ARDT's quarterly revenue has held near $1.6B with year-over-year growth decelerating to 2.7% in 2026Q3, suggesting top-line expansion has largely stalled after the 2025 peak.

The revenue series shows a flat trajectory across the last several quarters, with growth swinging between roughly 1% and 4% after reaching 4.4% in 2025Q2. This pattern suggests volume recovery is offsetting limited pricing realization rather than driving meaningful acceleration. Investors should monitor whether same-facility admissions growth of 2.9% can translate into sustained top-line growth or whether payer mix shifts toward government programs cap net revenue per admission.

Reported Gross Margin Reflects Classification Choices

As reported in financial statements, ARDT's gross margin swung from 82.7% to 15.9% across recent quarters, a shift that appears driven by cost reclassification rather than underlying pricing power.

The dramatic gross margin variation, including the drop from 83.6% in 2025Q2 to 42.1% in 2025Q4, indicates that the classification of clinical labor and supply costs between cost of revenue and operating expenses has changed over time. Because of this inconsistency, gross margin is not a reliable standalone indicator for peer comparison. Operating margin, which has ranged from roughly 2.7% to 16.1%, offers a more stable basis, though it remains thin for the sector.

EPS Volatility Diverges From EBITDA Commentary

According to reported earnings, ARDT's diluted EPS fell to $0.31 in 2026Q3 against a $0.35 consensus, while management cited adjusted EBITDA of $138 million, leaving a gap that warrants further investigation.

The disconnect between operational commentary and reported EPS suggests that below-EBITDA items such as depreciation, interest, or non-operating charges may be absorbing operating gains. The negative net income in 2025Q3 against positive operating income of $254.3M further underscores how non-operating items can dominate reported earnings. Investors should examine the reconciliation between adjusted and GAAP figures before drawing conclusions about underlying earnings power.

Labor Expense Discipline Under Scrutiny

Based on ARDT's reported figures, SG&A expense has run between $376M and $1.0B per quarter, and management's cited 4% reduction in salaries, wages, and benefits signals early progress on the labor cost pressures.

Clinical labor appears to be the dominant cost driver, and the reported 4% SWB reduction suggests management is gaining traction on premium contract labor spend. The sharp drop in SG&A from roughly $1.0B to $376M across 2025 likely reflects reclassification rather than pure savings, limiting conclusions about efficiency. Sustained wage discipline will be the key determinant of whether the 5.1% operating margin can expand.

Thin Margins Leave Little Cushion

The strongest bear case is that ARDT's 2.1% net margin, 1.34 debt-to-equity ratio, and 8.5% ROE leave limited room to absorb labor inflation or reductions in government supplemental payments.

Short-side analysis would focus on consecutive EPS misses and the 76.9% year-over-year EPS decline in 2026Q2 as evidence of earnings fragility. If government reimbursement pressure intensifies while wage inflation persists, the thin spread between revenue and earnings could compress further. Investors should monitor whether the reported margin improvements prove durable or are offset by recurring below-the-line charges.

ARDT — Frequently Asked Questions

Quick answers to the most common questions about buying ARDT stock.

What was Ardent Health Inc.'s (ARDT) revenue in 2025?

For fiscal year 2025, Ardent Health Inc. (ARDT) reported total revenue of $6.32B. This represents a 200.4% increase compared to $2.11B in 2016.

Is Ardent Health Inc. (ARDT) profitable?

Ardent Health Inc. (ARDT) is profitable, generating $135.8M in net income for the fiscal year ending 2025 with a net profit margin of 2.1%.

What is Ardent Health Inc.'s operating profit margin?

Ardent Health Inc. (ARDT) reported an operating income of $325.6M, resulting in an operating profit margin of 5.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Ardent Health Inc.'s gross profit and gross margin?

Ardent Health Inc. (ARDT) generated $6.17B in gross profit for the year, representing a gross profit margin of 97.5%. This demonstrates the company's core pricing power and production efficiency.